Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pretargeted Anti-CD20 RIT with BEAM and ASCT for B-cell Malignancies
NCT02483000Phase 1Terminated
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Feb 2017
- Primary completion
- Nov 2019
- Modality
- scFv Fragments, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of anti-CD20 B9E9 scFv-streptavidin fusion protein and avidin-biotin-dota-90y in B-cell non-Hodgkin lymphoma, Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL) and 2 more, sponsored by Fred Hutchinson Cancer Center. Started Feb 2017; status: terminated.
02
Drugs
anti-CD20 B9E9 scFv-streptavidin fusion proteinavidin-biotin-dota-90y
03
Conditions
B-cell non-Hodgkin lymphomaBurkitt lymphoma (BL)diffuse large B-cell lymphoma (DLBCL)mantle cell lymphoma (MCL)Indolent Non-Hodgkin Lymphoma (INHL)
Beyond the preview
Go deeper on NCT02483000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02483000.